Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?

Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, Ripin D, Flexner C, Domanico PL.

AIDS. 2018 Jul 31;32(12):1551-1561. doi: 10.1097/QAD.0000000000001845.

PMID:
29746295
2.

CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.

Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, Vitoria M, Doherty M, Meintjes G.

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S152-S159. doi: 10.1093/cid/cix1143.

3.

Managing Advanced HIV Disease in a Public Health Approach.

Ford N, Meintjes G, Calmy A, Bygrave H, Migone C, Vitoria M, Penazzato M, Vojnov L, Doherty M; Guideline Development Group for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy .

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S106-SS110. doi: 10.1093/cid/cix1139.

4.

Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat All.

Ford N, Vitoria M, Doherty M.

J Int AIDS Soc. 2018 Feb;21(2). doi: 10.1002/jia2.25078. No abstract available.

5.

The growing burden of noncommunicable disease among persons living with HIV in Zimbabwe.

Smit M, Olney J, Ford NP, Vitoria M, Gregson S, Vassall A, Hallett TB.

AIDS. 2018 Mar 27;32(6):773-782. doi: 10.1097/QAD.0000000000001754.

6.

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.

Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S; Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.

Lancet HIV. 2018 Mar;5(3):e146-e154. doi: 10.1016/S2352-3018(17)30190-X. Epub 2017 Nov 22.

7.

Benefits and risks of rapid initiation of antiretroviral therapy.

Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, Mills EJ, Meintjes G, Vitoria M, Doherty M, Shubber Z.

AIDS. 2018 Jan 2;32(1):17-23. doi: 10.1097/QAD.0000000000001671.

8.

The WHO public health approach to HIV treatment and care: looking back and looking ahead.

Ford N, Ball A, Baggaley R, Vitoria M, Low-Beer D, Penazzato M, Vojnov L, Bertagnolio S, Habiyambere V, Doherty M, Hirnschall G.

Lancet Infect Dis. 2018 Mar;18(3):e76-e86. doi: 10.1016/S1473-3099(17)30482-6. Epub 2017 Oct 20. Review.

PMID:
29066132
9.

Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis.

Kanters S, Socias ME, Paton NI, Vitoria M, Doherty M, Ayers D, Popoff E, Chan K, Cooper DA, Wiens MO, Calmy A, Ford N, Nsanzimana S, Mills EJ.

Lancet HIV. 2017 Oct;4(10):e433-e441. doi: 10.1016/S2352-3018(17)30109-1. Epub 2017 Aug 4.

PMID:
28784426
10.

Clinical and public health implications of acute and early HIV detection and treatment: a scoping review.

Rutstein SE, Ananworanich J, Fidler S, Johnson C, Sanders EJ, Sued O, Saez-Cirion A, Pilcher CD, Fraser C, Cohen MS, Vitoria M, Doherty M, Tucker JD.

J Int AIDS Soc. 2017 Jun 28;20(1):21579. doi: 10.7448/IAS.20.1.21579. Review.

11.

When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.

Vitoria M, Ford N, Clayden P, Pozniak AL, Hill AM.

Curr Opin HIV AIDS. 2017 Jul;12(4):414-422. doi: 10.1097/COH.0000000000000380. Review.

12.

Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable?

Ford N, Vitoria M, Doherty M, Gray A.

Curr Opin HIV AIDS. 2017 Jul;12(4):334-338. doi: 10.1097/COH.0000000000000377. Review.

PMID:
28403026
13.

Rapid diagnosis of tuberculosis. Detection of drug resistance mechanisms.

Viñuelas-Bayón J, Vitoria MA, Samper S.

Enferm Infecc Microbiol Clin. 2017 Oct;35(8):520-528. doi: 10.1016/j.eimc.2017.01.015. Epub 2017 Mar 15. English, Spanish.

PMID:
28318570
14.

Diversity and genetic stability in banana genotypes in a breeding program using inter simple sequence repeats (ISSR) markers.

Silva AV, Nascimento AL, Vitória MF, Rabbani AR, Soares AN, Lédo AS.

Genet Mol Res. 2017 Feb 23;16(1). doi: 10.4238/gmr16019402.

PMID:
28252170
15.

Diagnosis and monitoring of HIV programmes to support treatment initiation and follow up and improve programme quality.

Venter WD, Ford N, Vitoria M, Stevens W.

Curr Opin HIV AIDS. 2017 Mar;12(2):117-122. doi: 10.1097/COH.0000000000000354. Review.

PMID:
28134712
16.

The evolving role of CD4 cell counts in HIV care.

Ford N, Meintjes G, Vitoria M, Greene G, Chiller T.

Curr Opin HIV AIDS. 2017 Mar;12(2):123-128. doi: 10.1097/COH.0000000000000348. Review.

PMID:
28059957
17.

Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.

Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ.

Lancet HIV. 2016 Nov;3(11):e510-e520. doi: 10.1016/S2352-3018(16)30091-1. Epub 2016 Sep 6. Review.

PMID:
27658869
18.

Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.

Gupta A, Juneja S, Vitoria M, Habiyambere V, Nguimfack BD, Doherty M, Low-Beer D.

PLoS One. 2016 Oct 13;11(10):e0164619. doi: 10.1371/journal.pone.0164619. eCollection 2016.

19.

Genetic diversity in natural populations of mangaba in Sergipe, the largest producer State in Brazil.

Soares AN, Vitória MF, Nascimento AL, Ledo AS, Rabbani AR, Silva AV.

Genet Mol Res. 2016 Aug 19;15(3). doi: 10.4238/gmr.15038624.

PMID:
27706595
20.

Persistent infectious and tropical diseases in immigrant correctional populations.

Getaz L, Da Silva-Santos L, Wolff H, Vitoria M, Serre-Delcor N, Lozano-Becerra JC, Chappuis F, Albajar-Viñas P.

Rev Esp Sanid Penit. 2016 Oct;18(2):57-66. doi: 10.4321/S1575-06202016000200004. Review.

21.

The Role of ARV Associated Adverse Drug Reactions in Influencing Adherence Among HIV-Infected Individuals: A Systematic Review and Qualitative Meta-Synthesis.

Li H, Marley G, Ma W, Wei C, Lackey M, Ma Q, Renaud F, Vitoria M, Beanland R, Doherty M, Tucker JD.

AIDS Behav. 2017 Feb;21(2):341-351. doi: 10.1007/s10461-016-1545-0. Review.

22.

Tenofovir resistance and first-line antiretroviral therapy.

Ford N, Vitoria M, Doherty M, Bertagnolio S.

Lancet Infect Dis. 2016 Aug;16(8):890-1. doi: 10.1016/S1473-3099(16)30137-2. No abstract available.

PMID:
27477976
23.

Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy.

Waldrop G, Doherty M, Vitoria M, Ford N.

Trop Med Int Health. 2016 Sep;21(9):1124-30. doi: 10.1111/tmi.12746. Epub 2016 Jul 22.

24.

Implications of prioritizing HIV cure: new momentum to overcome old challenges in HIV.

Tucker JD, Gilbertson A, Lo YR, Vitória M.

BMC Infect Dis. 2016 Mar 3;16:109. doi: 10.1186/s12879-016-1445-y.

25.

Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

Vitoria M, Hill AM, Ford NP, Doherty M, Khoo SH, Pozniak AL.

J Int AIDS Soc. 2016 Feb 2;19(1):20504. doi: 10.7448/IAS.19.1.20504. eCollection 2016.

26.

Sustainable HIV treatment in Africa through viral-load-informed differentiated care.

Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa, Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, Bonner K, Rousseau C, Garnett G, Cambiano V, Nakagawa F, Ford D, Bansi-Matharu L, Miners A, Lundgren JD, Eaton JW, Parkes-Ratanshi R, Katz Z, Maman D, Ford N, Vitoria M, Doherty M, Dowdy D, Nichols B, Murtagh M, Wareham M, Palamountain KM, Chakanyuka Musanhu C, Stevens W, Katzenstein D, Ciaranello A, Barnabas R, Braithwaite RS, Bendavid E, Nathoo KJ, van de Vijver D, Wilson DP, Holmes C, Bershteyn A, Walker S, Raizes E, Jani I, Nelson LJ, Peeling R, Terris-Prestholt F, Murungu J, Mutasa-Apollo T, Hallett TB, Revill P.

Nature. 2015 Dec 3;528(7580):S68-76. doi: 10.1038/nature16046.

27.

Generating Evidence to Improve the Response to Neglected Diseases: How Operational Research in a Médecins Sans Frontières Buruli Ulcer Treatment Programme Informed International Management Guidance.

O'Brien DP, Ford N, Vitoria M, Asiedu K, Calmy A, Du Cros P, Comte E, Christinet V.

PLoS Negl Trop Dis. 2015 Nov 12;9(11):e0004075. doi: 10.1371/journal.pntd.0004075. eCollection 2015 Nov. No abstract available.

28.

Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.

Suthar AB, Vitoria MA, Nagata JM, Anglaret X, Mbori-Ngacha D, Sued O, Kaplan JE, Doherty MC.

Lancet HIV. 2015 Apr;2(4):e137-50. doi: 10.1016/S2352-3018(15)00005-3. Epub 2015 Mar 3. Review.

PMID:
26424674
29.

Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.

Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, Bennett D, Raizes E, Nakagawa F, De Luca A, Vitoria M, Barcarolo J, Perriens J, Jordan MR, Bertagnolio S.

Lancet HIV. 2014 Nov;1(2):e85-93. doi: 10.1016/S2352-3018(14)70021-9. Epub 2014 Oct 14.

30.

Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis.

Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, Davies MA, Vitoria M, Penazzato M, Nsanzimana S, Frigati L, O'Brien D, Ellman T, Ajose O, Calmy A, Doherty M.

Lancet HIV. 2015 Oct;2(10):e438-44. doi: 10.1016/S2352-3018(15)00137-X. Epub 2015 Aug 11. Review.

PMID:
26423651
31.

Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.

Nsanzimana S, Remera E, Kanters S, Forrest JI, Ford N, Condo J, Binagwaho A, Bucher H, Thorlund K, Vitoria M, Mills EJ.

Lancet HIV. 2015 Sep;2(9):e376-84. doi: 10.1016/S2352-3018(15)00112-5. Epub 2015 Aug 4. Erratum in: Lancet HIV. 2015 Sep;2(9):e364.

PMID:
26423551
32.

Co-trimoxazole in people on antiretroviral therapy for HIV--authors' reply.

Suthar AB, Vitoria MA, Doherty MC.

Lancet HIV. 2015 Jun;2(6):e227-8. doi: 10.1016/S2352-3018(15)00085-5. Epub 2015 May 27. No abstract available.

PMID:
26423193
33.

Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.

Ford N, Shubber Z, Calmy A, Irvine C, Rapparini C, Ajose O, Beanland RL, Vitoria M, Doherty M, Mayer KH.

Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S170-6. doi: 10.1093/cid/civ092. Review.

PMID:
25972499
34.

In Vivo IS6110 Profile Changes in a Mycobacterium tuberculosis Strain as Determined by Tracking over 14 Years.

Millán-Lou MI, Otal I, Monforte ML, Vitoria MA, Revillo MJ, Martín C, Samper S.

J Clin Microbiol. 2015 Jul;53(7):2359-61. doi: 10.1128/JCM.00607-15. Epub 2015 May 6.

35.

Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.

Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, Calmy A.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):422-9. doi: 10.1097/QAI.0000000000000606. Review.

PMID:
25850607
36.

CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy.

Peeling RW, Sollis KA, Glover S, Crowe SM, Landay AL, Cheng B, Barnett D, Denny TN, Spira TJ, Stevens WS, Crowley S, Essajee S, Vitoria M, Ford N.

PLoS One. 2015 Mar 19;10(3):e0115019. doi: 10.1371/journal.pone.0115019. eCollection 2015. Review.

37.

Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis.

Ford N, Irvine C, Shubber Z, Baggaley R, Beanland R, Vitoria M, Doherty M, Mills EJ, Calmy A.

AIDS. 2014 Nov 28;28(18):2721-7. doi: 10.1097/QAD.0000000000000505. Review.

PMID:
25493598
38.

The future role of CD4 cell count for monitoring antiretroviral therapy.

Ford N, Meintjes G, Pozniak A, Bygrave H, Hill A, Peter T, Davies MA, Grinsztejn B, Calmy A, Kumarasamy N, Phanuphak P, deBeaudrap P, Vitoria M, Doherty M, Stevens W, Siberry GK.

Lancet Infect Dis. 2015 Feb;15(2):241-7. doi: 10.1016/S1473-3099(14)70896-5. Epub 2014 Nov 19. Review.

PMID:
25467647
39.

Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings.

Vitoria M, Ford N, Doherty M, Flexner C.

Antivir Ther. 2014;19 Suppl 3:31-7. doi: 10.3851/IMP2898. Epub 2014 Oct 13. Review.

PMID:
25310534
40.

Editorial commentary: Comparative efficacy of lamivudine and emtricitabine: comparing the results of randomized trials and cohorts.

Ford N, Hill A, Vitoria M, Mills EJ.

Clin Infect Dis. 2015 Jan 1;60(1):154-6. doi: 10.1093/cid/ciu767. Epub 2014 Oct 1. No abstract available.

41.

Antiretroviral therapy response among HIV-2 infected patients: a systematic review.

Ekouevi DK, Tchounga BK, Coffie PA, Tegbe J, Anderson AM, Gottlieb GS, Vitoria M, Dabis F, Eholie SP.

BMC Infect Dis. 2014 Aug 26;14:461. doi: 10.1186/1471-2334-14-461. Review.

42.

Management of BU-HIV co-infection.

O'Brien DP, Ford N, Vitoria M, Christinet V, Comte E, Calmy A, Stienstra Y, Eholie S, Asiedu K.

Trop Med Int Health. 2014 Sep;19(9):1040-7. doi: 10.1111/tmi.12342. Epub 2014 Jun 20. Review.

43.

Developing the 2013 WHO consolidated antiretroviral guidelines.

Easterbrook PJ, Irvine CJ, Vitoria M, Shaffer N, Muhe LM, Negussie EK, Doherty MC, Ball A, Hirnschall G.

AIDS. 2014 Mar;28 Suppl 2:S93-100. doi: 10.1097/QAD.0000000000000253. No abstract available.

PMID:
24849484
44.

Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines.

Nelson LJ, Beusenberg M, Habiyambere V, Shaffer N, Vitoria MA, Montero RG, Easterbrook PJ, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S217-24. doi: 10.1097/QAD.0000000000000239.

PMID:
24849481
45.

Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure.

Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, Penazzato M, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S161-9. doi: 10.1097/QAD.0000000000000236. Review.

PMID:
24849476
46.

Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review.

Tucker JD, Bien CH, Easterbrook PJ, Doherty MC, Penazzato M, Vitoria M, Peeling RW.

AIDS. 2014 Mar;28 Suppl 2:S151-60. doi: 110.1097/QAD.0000000000000230. Review.

PMID:
24849475
47.

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.

Ford N, Mofenson L, Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Shaffer N, Renaud F.

AIDS. 2014 Mar;28 Suppl 2:S123-31. doi: 10.1097/QAD.0000000000000231. Review.

PMID:
24849471
48.

Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review.

Anglemyer A, Rutherford GW, Easterbrook PJ, Horvath T, Vitória M, Jan M, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S105-18. doi: 10.1097/QAD.0000000000000232. Review.

PMID:
24849469
49.

Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy.

Ramjan R, Calmy A, Vitoria M, Mills EJ, Hill A, Cooke G, Ford N.

Trop Med Int Health. 2014 May;19(5):501-13. doi: 10.1111/tmi.12297. Epub 2014 Mar 17. Review.

50.

Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis.

Smit PW, Sollis KA, Fiscus S, Ford N, Vitoria M, Essajee S, Barnett D, Cheng B, Crowe SM, Denny T, Landay A, Stevens W, Habiyambere V, Perriens JH, Peeling RW.

PLoS One. 2014 Mar 6;9(3):e86461. doi: 10.1371/journal.pone.0086461. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center